Boston Sci gets go-ahead to sell MRI-compatible spine stimulators

Boston Scientific has received FDA approval to go to market with an MRI-compatible version of one of its implantable spinal-cord stimulators used to relieve chronic pain.

Spinal cord stimulators deliver electrical pulses to block pain signals traveling to the brain. The new device, called the Precision Montage MRI Spinal Cord Stimulator (SCS), enables safe access to full-body scans in a 1.5T environment when conditions of use are met, according to an announcement from the Marlborough, Mass.-based company.

Boston Scientific says its new SCS system expands its suite of SCS products tapping the company’s trademarked Illumina 3D algorithm, which enables point-and-click pain targeting, as well as its multi-waveform technology, which is intended to respond to changes in pain over time.

The company says an analysis of registry information from 800 patients showed that 72 percent used multiple waveforms to customize their therapy and optimize pain relief.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.